TransThera Announces Global Phase 3 Trial for Cholangiocarcinoma and ODD
Details : TT-00420 (Tinengotinib), a next-generation FGFR inhibitor with, showning promising clinical benefit in subjects with FGFR-altered metastatic CCA.
Brand Name : TT-00420
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2024
Details : TT-00420 (tinengotinib), which is an investigational next-generation FGFR inhibitor. currently, it is being evaluated in the Phase III clinical trial studies with patients for the treatment of advanced FGFR-altered cholangiocarcinoma.
Brand Name : TT-00420
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Details : TT-00420 is spectrum selective kinase inhibitor that is found to show high potency to a variety of clinically identified FGFR2 mutations in preclinical experiments. A large number of preclinical studies have found that TT-00420 has promising inhibitory e...
Brand Name : TT-00420
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2021
LOOKING FOR A SUPPLIER?
Reset All
